---
title: "Pfizer's third-quarter revenue was $16.65 billion, estimated at $16.59 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264209132.md"
description: "Pfizer's revenue for the third quarter was $16.65 billion, exceeding the estimated $16.59 billion. The adjusted earnings per share were $0.87, with a full-year revenue forecast of $61 billion to $64 billion, and the adjusted earnings per share expectation raised to $3 to $3.15. Pfizer's stock rose over 2% in pre-market trading"
datetime: "2025-11-04T11:50:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264209132.md)
  - [en](https://longbridge.com/en/news/264209132.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264209132.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264209132.md) | [繁體中文](https://longbridge.com/zh-HK/news/264209132.md)


# Pfizer's third-quarter revenue was $16.65 billion, estimated at $16.59 billion

Pfizer's adjusted earnings per share for the third quarter were $0.87. Pfizer still forecasts full-year revenue of $61 billion to $64 billion. Pfizer expects full-year adjusted earnings per share of $3 to $3.15, up from the previous estimate of $2.90 to $3.10. Pfizer's U.S. stock rose more than 2% in pre-market trading.

Risk Warning and Disclaimer

The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at your own risk

### Related Stocks

- [Pfizer Inc. (PFE.US)](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors](https://longbridge.com/en/news/281219504.md)
- [Why Pfizer's 2026 guidance miss is 'not a major surprise'](https://longbridge.com/en/news/269888057.md)
- [(PFE) Pfizer Expects 2026 Adjusted EPS Range $2.80 to $3, vs. FactSet Est of $3.05](https://longbridge.com/en/news/269859022.md)
- [Fosun Pharmaceutical says unit signs GLP-1R licensing agreement with Pfizer](https://longbridge.com/en/news/269074234.md)
- [E. Ohman J or Asset Management AB Purchases Shares of 140,617 Pfizer Inc. $PFE](https://longbridge.com/en/news/280283368.md)